Preferred Label : deucravacitinib;
CISMeF synonym : BMS-986165;
UNII : N0A21N6RAU;
Origin ID : C000628674;
UMLS CUI : C5420928;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3563547/fr/depistage-de-la-tuberculose-latente-via-un-test-de-detection-de-la-production-d-interferon-gamma-igra-avant-initiation-d-un-traitement-par-un-medicament-de-la-classe-des-anti-jak-dont-sotyktu-deucravacitinib
2024
France
health technology assessment
drug therapy
tuberculosis, nos
production
filing
deucravacitinib
latent tuberculosis
interferon-gamma release tests
screening
economics
gamma interferon
interferon-gamma
deucravacitinib
Janus Kinase Inhibitors
detective
drug, nos
mass screening
tuberculosis
dermatomyositis
---
https://www.ema.europa.eu/en/medicines/human/EPAR/sotyktu
2023
false
false
false
Netherlands
French
English
drug approval
deucravacitinib
deucravacitinib
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
europe
adult
psoriasis
administration, oral
dermatologic agents
dermatologic agents
Janus Kinase Inhibitors
Janus Kinase Inhibitors
TYK2 kinase
deucravacitinib
product surveillance, postmarketing
continuity of patient care
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
---
https://www.has-sante.fr/jcms/p_3479044/fr/sotyktu-deucravacitinib-psoriasis-en-plaques
2023
false
false
false
France
administration, oral
treatment outcome
insurance, health, reimbursement
Janus Kinase Inhibitors
deucravacitinib
adult
evaluation of the transparency committee
deucravacitinib
psoriasis
---
https://www.cadth.ca/fr/deucravacitinib
2022
false
false
false
Canada
French
English
deucravacitinib
insurance, health, reimbursement
canada
drug evaluation
psoriasis
adult
---